Key result
Procoagulant platelets show potential as biomarkers for thrombotic events and targets for novel antithrombotic therapies.
Design
Review
Authors
Loading...
May guide antithrombotic target selection; leaves open clinical adoption until prospective validation.
This review unifies the terminology for procoagulant platelets and identifies novel therapeutic targets, such as carbonic anhydrase and Aquaporin-1, for antithrombotic drug development.
Agbani et al. (2017) conducted a review in Thrombosis. Procoagulant platelets represent a unified subpopulation of activated platelets with potential as biomarkers for thrombotic events and targets for novel antithrombotic therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: